{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:31:20Z","timestamp":1789144280702,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Unlike hyperprolactinemia, clinical significance of prolactin deficiency remains poorly understood. The aim of this study was to assess the cardiometabolic profile of patients with low prolactin levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study population consisted of three groups of young women. Two groups were chronically treated with cabergoline but differed in prolactin levels, which were either abnormally low (group A;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) or within the reference range (group B,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923). Group C, serving as a control group, included 28 drug-na\u00efve women with normal prolactin levels. The dose of cabergoline in group A was then tapered down. Glucose homeostasis markers, plasma lipids and circulating levels of hormones, uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen and homocysteine, as well as the carotid intima-media thickness were assessed at baseline and 6 months later.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with subjects with normal prolactin levels, women with hypoprolactinemia had higher levels of 2-h postchallenge glucose, glycated hemoglobin, triglycerides, uric acid, hsCRP and fibrinogen, lower values of HDL-cholesterol, total testosterone and free androgen index, as well as reduced insulin sensitivity. No differences in these variables were observed between groups B and C. Apart from prolactin normalization, cabergoline dose reduction reversed all laboratory disturbances reported in group A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The obtained results suggest that hypoprolactinemia in women of reproductive age may increase cardiometabolic risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-022-03145-1","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:02:28Z","timestamp":1659110548000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Cardiometabolic profile of young women with hypoprolactinemia"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-2620","authenticated-orcid":false,"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Kowalcze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"3145_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","volume":"13","author":"RS Auriemma","year":"2018","unstructured":"R.S. Auriemma, D. De Alcubierre, R. Pirchio, R. Pivonello, A. Colao, The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev. Endocrinol. Metab. 13, 99\u2013106 (2018). https:\/\/doi.org\/10.1080\/17446651.2018.1434412","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"3145_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000486000","volume":"49","author":"M Andersen","year":"2018","unstructured":"M. Andersen, D. Glintborg, Metabolic syndrome in hyperprolactinemia. Front. Horm. Res. 49, 29\u201347 (2018). https:\/\/doi.org\/10.1159\/000486000","journal-title":"Front. Horm. Res."},{"key":"3145_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1530\/eje.0.1490187","volume":"149","author":"D Yavuz","year":"2003","unstructured":"D. Yavuz, O. Deyneli, I. Akpinar, E. Yildiz, H. G\u00f6z\u00fc, O. Sezgin, G. Haklar, S. Akalin, Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur. J. Endocrinol. 149, 187\u2013193 (2003). https:\/\/doi.org\/10.1530\/eje.0.1490187","journal-title":"Eur. J. Endocrinol."},{"key":"3145_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4158\/EP13173.OR","volume":"20","author":"MS Arslan","year":"2014","unstructured":"M.S. Arslan, O. Topaloglu, M. Sahin, E. Tutal, A. Gungunes, E. Cakir, I.U. Ozturk, B. Karbek, B. Ucan, Z. Ginis, E. Cakal, M. Ozbek, T. Delibasi, Preclinical atherosclerosis in patients with prolactinoma. Endocr. Pract. 20, 447\u2013451 (2014). https:\/\/doi.org\/10.4158\/EP13173.OR","journal-title":"Endocr. Pract."},{"key":"3145_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bcpt.12307","volume":"116","author":"R Krysiak","year":"2015","unstructured":"R. Krysiak, B. Okopie\u0144, Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin. Pharmacol. Toxicol. 116, 251\u2013256 (2015). https:\/\/doi.org\/10.1111\/bcpt.12307","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"3145_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"R.S. Auriemma, L. Granieri, C. Simeoli, P. Vitale, C. Pivonello, M. Negri, T. Mannarino, C. Giordano, M. Gasperi, A. Colao, R. Pivonello, Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98, 299\u2013310 (2013). https:\/\/doi.org\/10.1159\/000357810","journal-title":"Neuroendocrinology"},{"key":"3145_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jcph.1301","volume":"59","author":"R Krysiak","year":"2019","unstructured":"R. Krysiak, W. Szkr\u00f3bka, B. Okopie\u0144, Different effects of atorvastatin on cardiometabolic risk factors in young women with and without hyperprolactinemia. J. Clin. Pharm. 59, 83\u201389 (2019). https:\/\/doi.org\/10.1002\/jcph.1301","journal-title":"J. Clin. Pharm."},{"key":"3145_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pharep.2018.09.004","volume":"71","author":"R Krysiak","year":"2019","unstructured":"R. Krysiak, W. Szkr\u00f3bka, B. Okopie\u0144, Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. Pharmacol. Rep. 71, 61\u201366 (2019). https:\/\/doi.org\/10.1016\/j.pharep.2018.09.004","journal-title":"Pharmacol. Rep."},{"key":"3145_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","volume":"15","author":"V Bernard","year":"2019","unstructured":"V. Bernard, J. Young, N. Binart, Prolactin - a pleiotropic factor in health and disease. Nat. Rev. Endocrinol. 15, 356\u2013365 (2019). https:\/\/doi.org\/10.1038\/s41574-019-0194-6","journal-title":"Nat. Rev. Endocrinol."},{"key":"3145_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/cen.14283","volume":"93","author":"R Krysiak","year":"2020","unstructured":"R. Krysiak, K. Kowalcze, B. Okopie\u0144, Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin. Endocrinol. (Oxf.) 93, 482\u2013488 (2020). https:\/\/doi.org\/10.1111\/cen.14283","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"3145_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.endien.2021.03.004","volume":"69","author":"R Krysiak","year":"2022","unstructured":"R. Krysiak, K. Kowalcze, B. Okopie\u0144, Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: a pilot study. Endocrinol. Diabetes Nutr. (Engl. Ed.) 69, 279\u2013288 (2022). https:\/\/doi.org\/10.1016\/j.endien.2021.03.004","journal-title":"Endocrinol. Diabetes Nutr. (Engl. Ed.)"},{"key":"3145_CR12","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","volume":"6","author":"G Corona","year":"2009","unstructured":"G. Corona, E. Mannucci, E.A. Jannini, F. Lotti, V. Ricca, M. Monami, V. Boddi, E. Bandini, G. Balercia, G. Forti, M. Maggi, Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J. Sex. Med. 6, 1457\u20131466 (2009). https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01206.x","journal-title":"J. Sex. Med."},{"key":"3145_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s43440-021-00347-8","volume":"74","author":"R Krysiak","year":"2022","unstructured":"R. Krysiak, K. Kowalcze, B. Okopie\u0144, Impaired metabolic effects of metformin in men with early-onset androgenic alopecia. Pharmacol. Rep. 74, 216\u2013228 (2022). https:\/\/doi.org\/10.1007\/s43440-021-00347-8","journal-title":"Pharmacol. Rep."},{"key":"3145_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.phrs.2018.01.007","volume":"129","author":"C Cuspidi","year":"2018","unstructured":"C. Cuspidi, C. Sala, M. Tadic, G. Grassi, G. Mancia, Carotid intima-media thickness and anti-hypertensive treatment: Focus on angiotensin II receptor blockers. Pharmacol. Res. 129, 20\u201326 (2018). https:\/\/doi.org\/10.1016\/j.phrs.2018.01.007","journal-title":"Pharmacol. Res."},{"key":"3145_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/2047487312448990","volume":"19","author":"PJ Touboul","year":"2012","unstructured":"P.J. Touboul, D.E. Grobbee, H. den Ruijter, Assessment of subclinical atherosclerosis by carotid intima media thickness: technical issues. Eur. J. Prev. Cardiol. 19, 18\u201324 (2012). https:\/\/doi.org\/10.1177\/2047487312448990","journal-title":"Eur. J. Prev. Cardiol."},{"key":"3145_CR16","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/S0140-6736(16)30053-8","volume":"388","author":"CE Higham","year":"2016","unstructured":"C.E. Higham, G. Johannsson, S.M. Shalet, Hypopituitarism. Lancet 388, 2403\u20132415 (2016). https:\/\/doi.org\/10.1016\/S0140-6736(16)30053-8","journal-title":"Lancet"},{"key":"3145_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2265.2010.03850","volume":"73","author":"CE Powe","year":"2010","unstructured":"C.E. Powe, M. Allen, K.M. Puopolo, A. Merewood, S. Worden, L.C. Johnson, A. Fleischman, C.K. Welt, Recombinant human prolactin for the treatment of lactation insufficiency. Clin. Endocrinol. 73, 645\u2013653 (2010). https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03850","journal-title":"Clin. Endocrinol."},{"key":"3145_CR18","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1542\/peds.2010-1627","volume":"127","author":"CE Powe","year":"2011","unstructured":"C.E. Powe, K.M. Puopolo, D.S. Newburg, B. L\u00f6nnerdal, C. Chen, M. Allen, A. Merewood, S. Worden, C.K. Welt, Effects of recombinant human prolactin on breast milk composition. Pediatrics 127, e359\u2013e366 (2011). https:\/\/doi.org\/10.1542\/peds.2010-1627","journal-title":"Pediatrics"},{"key":"3145_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/13697130701377265","volume":"10","author":"A Khatibi","year":"2007","unstructured":"A. Khatibi, C.D. Agardh, Y.A. Shakir, C. Nerbrand, P. Nyberg, J. Lidfeldt, G. Samsioe, Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women\u2019s Health in the Lund Area (WHILA) Study. Climacteric 10, 386\u2013392 (2007). https:\/\/doi.org\/10.1080\/13697130701377265","journal-title":"Climacteric"},{"key":"3145_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-06-0702","volume":"156","author":"E Debing","year":"2007","unstructured":"E. Debing, E. Peeters, W. Duquet, K. Poppe, B. Velkeniers, Van, P. den Brande, Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur. J. Endocrinol. 156, 687\u2013693 (2007). https:\/\/doi.org\/10.1530\/EJE-06-0702","journal-title":"Eur. J. Endocrinol."},{"key":"3145_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","volume":"64","author":"M De Rosa","year":"2006","unstructured":"M. De Rosa, A. Ciccarelli, S. Zarrilli, E. Guerra, M. Gaccione, A. Di Sarno, G. Lombardi, A. Colao, The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin. Endocrinol. 64, 307\u2013313 (2006). https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02461.x","journal-title":"Clin. Endocrinol."},{"key":"3145_CR22","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli, M. De Rosa, S. Zarrilli, G. Lombardi, Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704\u20131711 (2004). https:\/\/doi.org\/10.1210\/jc.2003-030979","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3145_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0065-1281(97)80043-8","volume":"99","author":"EL Gregoraszczuk","year":"1997","unstructured":"E.L. Gregoraszczuk, S. Stoklosowa, The effect of microtubule and microfilament-disrupting drugs on prolactin-stimulated progesterone synthesis and secretion by cultured porcine theca cells. Acta Histochem. 99, 207\u2013215 (1997). https:\/\/doi.org\/10.1016\/S0065-1281(97)80043-8","journal-title":"Acta Histochem."},{"key":"3145_CR24","doi-asserted-by":"publisher","unstructured":"H. Cohen, I. Sabbagh, P. Guillaumot, J.J. Bertrand, Steroid regulation of gonadotropins in genetically hypoprolactinemic females (IPL nude rats. Steroid Biochem 24, 431\u2013435 (1986). https:\/\/doi.org\/10.1016\/0022-4731(86)90096-8","DOI":"10.1016\/0022-4731(86)90096-8"},{"key":"3145_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1095\/biolreprod29.2.342","volume":"29","author":"CH Tsai-Morris","year":"1983","unstructured":"C.H. Tsai-Morris, M. Ghosh, A.N. Hirshfield, P.M. Wise, A.M. Brodie, Inhibition of ovarian aromatase by prolactin in vivo. Biol. Reprod. 29, 342\u2013346 (1983). https:\/\/doi.org\/10.1095\/biolreprod29.2.342","journal-title":"Biol. Reprod."},{"key":"3145_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jcte.2015.05.001","volume":"2","author":"CM Gorvin","year":"2015","unstructured":"C.M. Gorvin, The prolactin receptor: diverse and emerging roles in pathophysiology. J. Clin. Transl. Endocrinol. 2, 85\u201391 (2015). https:\/\/doi.org\/10.1016\/j.jcte.2015.05.001","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"3145_CR27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1139\/y2012-122","volume":"90","author":"RB Singh","year":"2012","unstructured":"R.B. Singh, S. Gupta, P. Dherange, F. De Meester, A. Wilczynska, S.E. Alam, D. Pella, D.W. Wilson, Metabolic syndrome: a brain disease. Can. J. Physiol. Pharm. 90, 1171\u20131183 (2012). https:\/\/doi.org\/10.1139\/y2012-122","journal-title":"Can. J. Physiol. Pharm."},{"key":"3145_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"M.E. Freeman, B. Kanyicska, A. Lerant, G. Nagy, Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523\u20131631 (2000). https:\/\/doi.org\/10.1152\/physrev.2000.80.4.1523","journal-title":"Physiol. Rev."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03145-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T08:19:22Z","timestamp":1663143562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03145-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["3145"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03145-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742260549.793595426","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from each patient before the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study protocol adhered to the principles of the Declaration of Helsinki was approved by the local institutional review board (the Bioethical Committee of the Medical University of Silesia [KNW\/0022\/KB\/232\/17]; October 17, 2017).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}